Meeting
2018 ASCO Annual Meeting
Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
Authors
David Samuel DiCapua Siegel
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
David Samuel DiCapua Siegel , Gary J. Schiller , Christy Joy Samaras , Michael Sebag , Jesus G. Berdeja , Siddhartha Ganguly , Jeffrey Matous , Kevin W. Song , Christopher Seet , Giampaolo Talamo , Shanthi Srinivas , Mirelis Acosta-Rivera , Michael Bar , Donald Quick , Bertrand Marquess Anz , Gustavo Fonseca , Donna Ellen Reece , Faiza Zafar , Weiyuan Chung , Nizar J. Bahlis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT01946477
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8027)
DOI
10.1200/JCO.2018.36.15_suppl.8027
Abstract #
8027
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee